BCL2 and neoplasm: For example, ZFP36 has tumour‐suppressive properties that are directly related to its ability to post‐transcriptionally regulate oncogenic mRNAs, including NOTCH1, MYC, BCL‐2, and COX‐2.[24, 25, 26] ZFP36 can also complement the function of tumour suppressors such as p53 and LATS2.[27, 28] In this study, we found that Zfp36SMKO mice developed a phenotype with decreased blood pressure under both physiological and pathological conditions by regulating the contraction of VSMCs, which enhances our understanding of the functions of ZFP36.